The controversial role of placental growth factor in tumor growth (Q37856508)

24 August 2017

1 reference

title

The controversial role of placental growth factor in tumor growth (English)

1 reference

24 August 2017

Domenico Ribatti

1 reference

24 August 2017

language of work or name

English

0 references

publication date

22 March 2011

1 reference

full work available at URL

24 August 2017

https://api.elsevier.com/content/article/PII:S0304383511001388?httpAccept=text/xml

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

https://api.elsevier.com/content/article/PII:S0304383511001388?httpAccept=text/plain

28 November 2024

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

28 November 2024

1 reference

24 August 2017

volume

307

1 reference

24 August 2017

1 reference

24 August 2017

page(s)

1-5

1 reference

Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

The crystal structure of human placenta growth factor-1 (PlGF-1), an angiogenic protein, at 2.0 A resolution

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Placenta growth factor: identification and characterization of a novel isoform generated by RNA alternative splicing

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Evidence of a novel isoform of placenta growth factor (PlGF-4) expressed in human trophoblast and endothelial cells

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Neuropilin-1 is a placenta growth factor-2 receptor

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Expression of vascular endothelial growth factor, placental growth factor, and their receptors Flt-1 and KDR in human placenta under pathologic conditions

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Placental growth factor mediates mesenchymal cell development, cartilage turnover, and bone remodeling during fracture repair

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Hypoxia increases placenta growth factor expression in human myocardium and cultured neonatal rat cardiomyocytes

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Placenta growth factor in diabetic wound healing: altered expression and therapeutic potential

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Involvement of placental growth factor in Wallerian degeneration

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Blockage of VEGF-induced angiogenesis by preventing VEGF secretion

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor.

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Down-regulation of placenta growth factor by promoter hypermethylation in human lung and colon carcinoma

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Plgf-/-eNos-/- mice show defective angiogenesis associated with increased oxidative stress in response to tissue ischemia

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Placental growth factor-1 attenuates vascular endothelial growth factor-A-dependent tumor angiogenesis during beta cell carcinogenesis

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Expression of Placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Placenta growth factor expression is correlated with survival of patients with colorectal cancer

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer.

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Placenta growth factor is over-expressed and has prognostic value in human breast cancer

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma.

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Placenta growth factor (PlGF) mRNA expression in brain tumors

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Vascular endothelial growth factor receptor-1 regulates postnatal angiogenesis through inhibition of the excessive activation of Akt

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

The molecular basis of VEGFR-1 signal transduction pathways in primary human monocytes

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

VEGFR1 tyrosine kinase signaling promotes lymphangiogenesis as well as angiogenesis indirectly via macrophage recruitment

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma.

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

VEGF signaling on hematopoietic precursors restricts B-lymphoid commitment in vitro and in vivo

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

The prognostic value of vascular endothelial growth factors (VEGFs)-A and -B and their receptor, VEGFR-1, in invasive breast carcinoma

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1.

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

PlGF blockade does not inhibit angiogenesis during primary tumor growth

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Further Pharmacological and Genetic Evidence for the Efficacy of PlGF Inhibition in Cancer and Eye Disease

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

sFLT01: A Novel Fusion Protein with Antiangiogenic Activity

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

28 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2011.02.043

28 November 2024

Identifiers

DOI

1 reference

24 August 2017

1 reference